NCI-H1563Homo sapiens (Human)Cancer cell line

Also known as: NCIH1563, H-1563, H1563

🤖 AI SummaryBased on 10 publications

Quick Overview

Human small cell lung cancer cell line with known RB1 mutations and potential for drug sensitivity studies.

Detailed Summary

The NCI-H1563 cell line is a human small cell lung cancer (SCLC) cell line derived from a patient with lung cancer. It is characterized by the presence of RB1 mutations, which are common in SCLC and play a critical role in cell cycle regulation and tumor suppression. This cell line has been used in studies investigating the molecular mechanisms of SCLC, including the role of RB1 in tumor progression and the identification of potential therapeutic targets. Research has shown that NCI-H1563 exhibits sensitivity to certain chemotherapeutic agents, making it a valuable model for drug sensitivity studies. Additionally, the cell line has been utilized in proteomic and genomic analyses to identify differentially expressed genes and pathways associated with SCLC, contributing to the understanding of the disease's molecular basis.

Research Applications

Molecular mechanisms of SCLCRB1 mutation analysisDrug sensitivity studiesProteomic and genomic analyses

Key Characteristics

RB1 mutationsSensitivity to chemotherapeutic agentsUsed in SCLC research
Generated on 6/17/2025

Basic Information

Database IDCVCL_1475
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Age CategoryUnknown
SexMale

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000892_source

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10,11
D13S317
9,14
D16S539
9,13
D18S51
13,17
D19S433
12,16
D21S11
28,30
D2S1338
16,22
D3S1358
16,17
D5S818
12,13
D7S820
7,8
D8S1179
13
FGA
21,23
Penta D
12,15
Penta E
10,13
TH01
6
TPOX
8,11
vWA
17,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources